In:
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Wiley, Vol. 1, No. 3 ( 2015-09), p. 334-338
Abstract:
Preventive measures, prognosis, or selected therapy in multifactorial maladies, including Alzheimer's disease (AD), require the application of a wide range of diagnostic assays. There is a large unmet need for relatively simple, blood‐based biomarkers in this regard. We have recently developed a rapid and reliable flow cytometry and antibody‐based method for the quantitative measurement of various red blood cell (RBC) membrane proteins from a drop of blood. Here, we document that the RBC expression of certain membrane proteins, especially that of the GLUT1 transporter and the insulin receptor (INSR), is significantly higher in AD patients than in age‐matched healthy subjects. The observed differences may reflect long‐term metabolic alterations relevant in the development of AD. These findings may pave the way for a diagnostic application of RBC membrane proteins as relatively stable and easily accessible personalized biomarkers in AD.
Type of Medium:
Online Resource
ISSN:
2352-8729
,
2352-8729
DOI:
10.1016/j.dadm.2015.06.007
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2832898-X
Permalink